Hikma Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hikma Pharmaceuticals
Public company (LSEHIK)
Industry Pharmaceutical
Founded 1978
Key people
Samih Darwazah Chairman
Said Darwazah CEO
Products Amoclan
Revenue US$1,489 million (2014)[1]
US$427 million (2014)[1]
US$282 million (2014)[1]
Number of employees
circa 6,000 (2012)
Slogan Improving people's quality of life globally
Website www.hikma.com

Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, that manufactures branded and non-branded generic and in-licensed pharmaceutical products. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index. In 2013, Hikma delivered 23% group revenue growth [2] and is the largest regional pharmaceutical company in the MENA region.[3] It was founded in Jordan in 1978 by Samih Darwazah.


The Company was founded by Samih Darwazah in 1978 in Amman in Jordan.[4] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[5] It was first listed on the London Stock Exchange in 2005.[4] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005[6] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.[4] In 2007 the Company went on to buy APM in Jordan,[7] Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia[7] Thymoorgan in Germany[4] and Ribosepharm in Germany.[4] It also acquired Multi-Source Injectables in the USA in October 2010.[8] In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).[9][10]

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco.[11] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.[12]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.[13]

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.[14] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market [15]

On May 28, 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.[16]


Hikma Pharmaceutical’s operations span over 50 countries with 26 manufacturing plants in 11 countries, and 7 R&D centers.[17] The Company's production facilities are located in the following countries: United States (FDA approved), Portugal (FDA approved), Italy, Jordan (FDA & MHRA approved), Saudi Arabia (FDA approved), Algeria, Germany (FDA approved), Egypt, Morocco, Tunisia, Sudan, Canada and Ethiopia.

Business Segments[edit]


Hikma’s branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Amoclan, Blopress, Omnicef, Prograf and Suprax.[18]


Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.[19]


Hikma’s oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol and prednisone.[17]

See also[edit]


External links[edit]